KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash from Financing Activities (2017 - 2025)

Alnylam Pharmaceuticals' Cash from Financing Activities history spans 17 years, with the latest figure at $45.3 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 46.2% year-over-year to $45.3 million; the TTM value through Dec 2025 reached -$305.2 million, down 203.75%, while the annual FY2025 figure was -$305.2 million, 203.75% down from the prior year.
  • Cash from Financing Activities reached $45.3 million in Q4 2025 per ALNY's latest filing, up from -$448.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $573.8 million in Q3 2021 to a low of -$448.3 million in Q3 2025.
  • Average Cash from Financing Activities over 5 years is $91.7 million, with a median of $48.8 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: soared 1580.5% in 2021, then tumbled 536.33% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $292.3 million in 2021, then plummeted by 78.3% to $63.4 million in 2022, then tumbled by 38.16% to $39.2 million in 2023, then dropped by 20.98% to $31.0 million in 2024, then surged by 46.2% to $45.3 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Cash from Financing Activities are $45.3 million (Q4 2025), -$448.3 million (Q3 2025), and $53.8 million (Q2 2025).